Recent Press Releases
| DATE |
TITLE (click to view) |
| February 18, 2010 | Antigenics Reports Fourth Quarter and Year-End 2009 Financial Results |
| February 11, 2010 | Antigenics to Report Fourth Quarter and Year-End 2009 Financial Results on February 18, 2010; Conference Call to Follow |
| December 31, 2009 | Antigenics Receives NASDAQ Delisting Notification |
| November 20, 2009 | European CHMP Formally Adopts Negative Opinion on Oncophage® |
| November 4, 2009 | Antigenics Provides Details On GlaxoSmithKline’s Pivotal Malaria Vaccine Trial With QS-21 Adjuvant |
| October 29, 2009 | Antigenics Reports Third Quarter 2009 Financial Results |
| October 26, 2009 | Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At SNO 2009 |
| October 22, 2009 | Antigenics to Report Third Quarter 2009 Financial Results on October 29, 2009; Conference Call to Follow |
| October 21, 2009 | Antigenics Announces a Negative Vote From the CHMP on Oncophage® Marketing Application in Europe |
| September 21, 2009 | Antigenics Announces Expansion of its QS-21 License Agreement |
| August 12, 2009 | Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage® Cancer Vaccine in Newly Diagnosed Glioma |
| August 4, 2009 | Antigenics to Raise $10 Million in Private Placement |
| July 31, 2009 | Antigenics to Raise $10 Million in Private Placement |
| July 30, 2009 | Antigenics Reports Second Quarter 2009 Financial Results |
| June 25, 2009 | Antigenics Announces Expansion of Investigator-Sponsored Study for Glioma |
| June 17, 2009 | Antigenics’ QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline’s Malaria Vaccine |
| June 15, 2009 | Tim Rothwell Joins Antigenics' Board of Directors |
| June 1, 2009 | Antigenics Presents Positive Oncophage® Interim Survival Data at ASCO |
| May 27, 2009 | Antigenics To Webcast 2009 Annual Shareholders Meeting |
| May 7, 2009 | Antigenics Reports First Quarter 2009 Financial Results |
| May 4, 2009 | Antigenics to Report First Quarter 2009 Financial Results on May 7, 2009; Conference Call to Follow |
| April 30, 2009 | Antigenics Regains NASDAQ Compliance |
| April 29, 2009 | FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma |
| March 12, 2009 | Antigenics’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Brain Cancer |
| February 19, 2009 | Antigenics Reports Fourth Quarter and Year-End 2008 Financial Results |
|
|
|
|
|
